Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Thomson

Showing results (891-900 of 901) with videos related to

Pageof 91
Sort By:
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
Nature|March 30, 2023
Adeno-associated virus 2 infection in children with non-A-E hepatitisAntonia Ho, Richard Orton, Rachel Tayler, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|October 6, 2020
Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)Chunxue Bai, Sanjay H Chotirmall, Jordi Rello, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Genome Biology|March 30, 2013
The western painted turtle genome, a model for the evolution of extreme physiological adaptations in a slowly evolving lineageH Bradley Shaffer, Patrick Minx, Daniel E Warren, et al.
Cell|February 23, 2021
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunityEmma C Thomson, Laura E Rosen, James G Shepherd, et al.
Plos Biology|February 25, 2021
A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 researchSuzannah J Rihn, Andres Merits, Siddharth Bakshi, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 91

Showing results (891-900 of 901) with videos related to

Sort By:
Pageof 91
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
Nature|March 30, 2023
Adeno-associated virus 2 infection in children with non-A-E hepatitisAntonia Ho, Richard Orton, Rachel Tayler, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|October 6, 2020
Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)Chunxue Bai, Sanjay H Chotirmall, Jordi Rello, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Genome Biology|March 30, 2013
The western painted turtle genome, a model for the evolution of extreme physiological adaptations in a slowly evolving lineageH Bradley Shaffer, Patrick Minx, Daniel E Warren, et al.
Cell|February 23, 2021
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunityEmma C Thomson, Laura E Rosen, James G Shepherd, et al.
Plos Biology|February 25, 2021
A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 researchSuzannah J Rihn, Andres Merits, Siddharth Bakshi, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 91